Evotec SE American Depositary Shares Q2 2025 Earnings Recap

EVO Q2 2025 August 13, 2025

Get alerts when EVO reports next quarter

Evotec SE reported a 5% decline in first-half 2025 revenues to EUR 371 million, reflecting challenges in the Discovery & Preclinical Development segment, while Just - Evotec Biologics continued to thrive with 16% revenue growth.

Earnings Per Share Beat

$-0.14 vs $-0.18 est.

+19.9% surprise

Revenue Beat

201618938 vs 191793920 est.

+5.1% surprise

Market Reaction

1-Day +0.26%

5-Day -6.3%

30-Day -8.14%

See EVO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Discovery & Preclinical Development revenues fell by 11%, impacted by temporary changes in the BMS collaboration and a soft drug discovery market.
Just - Evotec Biologics outperformed expectations, demonstrating strong demand and achieving 16% year-over-year revenue growth.
A planned sale of the Toulouse site to Sandoz aligns with Evotec's strategy to enhance its capabilities in biologics manufacturing with a scalable, asset-light model.
A strategic reorganization is underway to simplify the business structure and enhance operational accountability.
Market conditions remain challenging, particularly for early-stage biotech funding, but signs of recovery are emerging.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit EVO on AllInvestView.

Next Q3 2025